Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany

Lung Cancer

Volumn 69, Issue SUPPL. 1, 2010, Pages

  Bischoff, Helge G ^a   Heigener, David F ^b   Walzer, Stefan ^c   Nuijten, Mark ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Ars Accessus Medica   (Netherlands)

Author keywords

Bevacizumab; Cost; Non small cell lung cancer (NSCLC); Pemetrexed

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PEMETREXED;

ADVANCED CANCER; ARTICLE; BODY WEIGHT; COST BENEFIT ANALYSIS; GERMANY; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG COSTS; GERMANY; GLUTAMATES; GUANINE; HUMANS; ITALY; LUNG NEOPLASMS;

EID: 77956034961     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(10)70134-3     Document Type: Article

References (21)

1. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990 94 results and commentary. Ann Oncol 2003, 14(Suppl 5):v61-118.
2. Wilking N, Högberg D, Jönsson B. Benchmarking report of lung cancer care in selected European Countries. Karolinska Institutet/i3 Innovus, Stockholm School of Economics, 2008.
3. Toloza EM, Harpole L, McCrory DC Noninvasive staging of non- small cell lung cancer: a review of the current evidence. Chest 2003 January, 123(Suppl 1):137S-146S.
4. Wilking N, Jönsson B A pan-European comparison regarding patient access to cancer drugs 2005 Sept 7, Karolinska Institutet in collaboration with Stockholm School of Economics, Stockholm, Sweden.
5. Alexanian A, Torri V Survey on the treatment of non-small-cell lung caner in Italy. Ann Oncol 2000, 11:807-813.
6. Federal Health Monitoring (Germany). Todesursachenstatistik, Statistisches Bundesamt, Zweigstelle Bonn, 2009.
7. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
9. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non- small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27(8):1227-1234.
10. Ferrara N Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002, 29:10-14.
11. EMEA. Press Release (pemetrexed). Meeting highlights from the Committee for Medicinal Products for Human Use, 26 29 May 2009. Report No.: EMEA/CHMP/330580/2009.
12. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
13. Nuijten M, Heigener DF, Bischoff HG, Chouaid C, Vergnenègre A, de Castro Carpeño J, et al. Effectiveness of bevacizumaband pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010, 69(Suppl 1):S4-S10.
14. Sandler A, Yi J, Hambleton J, Kolb MM, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) Study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). International Association for the Study of Lung Cancer (IASLC) Chicago Multidisciplinary Symposium in Throracic Oncology, Chicago, IL, November 13 15, 2008, Poster 133.
15. Patel JD, Hensing TA, Rademaker F, Hart E, Obasaju CK, Treat J, et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(Suppl). abstract 8044.
16. Drummond MF, Mason AR European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007, 25(2):191-195.
17. Giuliani G, Grossi F, de Marinis F, Walzer S Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced nonsquamous NSCLC in Italy. Lung Cancer 2010, 69(Suppl 1):S11-S17.
18. Ciuleanu TE, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
19. Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004, 43(1):101-112.
20. Novello S, Kielhorn A, Stynes G, Selvaggi G, De Marinis F, Maestri A, et al. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 2005, 48(3):379-387.
21. Deeks JJ Issues in the selection of a summary statistic for meta- analysis of clinical trials with binary outcomes. Stat Med 2002, 21:1575-1600.